Marker Therapeutics, Inc. (NASDAQ:MRKR – Get Free Report) was the target of a significant growth in short interest in the month of October. As of October 30th, there was short interest totaling 176,136 shares, a growth of 61.4% from the October 15th total of 109,110 shares. Based on an average daily trading volume, of 255,474 shares, the short-interest ratio is presently 0.7 days. Approximately 1.1% of the company’s shares are short sold.
Marker Therapeutics Stock Up 1.5%
Shares of Marker Therapeutics stock traded up $0.01 during trading hours on Wednesday, reaching $0.85. 44,433 shares of the company’s stock were exchanged, compared to its average volume of 151,027. Marker Therapeutics has a 1 year low of $0.81 and a 1 year high of $2.46. The company has a market capitalization of $14.15 million, a P/E ratio of -2.18 and a beta of 1.65. The business has a fifty day moving average of $1.04 and a two-hundred day moving average of $1.31.
Marker Therapeutics (NASDAQ:MRKR – Get Free Report) last released its quarterly earnings data on Monday, November 16th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. The company had revenue of $1.29 million for the quarter, compared to analyst estimates of $2.12 million. As a group, research analysts predict that Marker Therapeutics will post -0.64 EPS for the current year.
Institutional Trading of Marker Therapeutics
Wall Street Analyst Weigh In
A number of equities analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Marker Therapeutics in a research report on Friday, August 21st. Weiss Ratings lowered Marker Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday. Finally, Zacks Research lowered shares of Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 13th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $10.00.
View Our Latest Analysis on MRKR
Marker Therapeutics Company Profile
Marker Therapeutics is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. Its platform aims to produce T cells that recognize multiple tumor-associated antigens, with the goal of helping them target cancer cells while reducing the risk that tumors evade treatment by losing a single antigen. The company’s pipeline includes multi-antigen-specific T-cell candidates for blood cancers. Its programs have included MT-601, studied for lymphoma, and MT-401, developed for acute myeloid leukemia and other hematologic malignancies.
See Also
- Five stocks we like better than Marker Therapeutics
- 5 Consumer Discretionary Plays Showing Strength During the Tech Sell-Off
- NVIDIA’s Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
Receive News & Ratings for Marker Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marker Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
